No headlines found.
Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Wed, 2-Sep 7:30 AM ET)
Globe Newswire (Mon, 31-Aug 4:05 PM ET)
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 13-Aug 4:02 PM ET)
Kyntra Bio to Report Second Quarter 2026 Financial Results
Globe Newswire (Thu, 6-Aug 9:00 AM ET)
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
Kyntra Bio trades on the NASDAQ stock market under the symbol KYNB.
As of September 24, 2026, KYNB stock price declined to $7.00 with 8,382 million shares trading.
KYNB has a beta of 1.04, meaning it tends to be more sensitive to market movements. KYNB has a correlation of 0.08 to the broad based SPY ETF.
KYNB has a market cap of $28.32 million. This is considered a Sub-Micro Cap stock.
Last quarter Kyntra Bio reported $-1 million in Revenue and -$4.68 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$1.50.
The top ETF exchange traded funds that KYNB belongs to (by Net Assets): VTI, VXF.
KYNB support price is $6.88 and resistance is $7.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KYNB shares will trade within this expected range on the day.